Community Health Systems, Inc. CYH 深 沪
等待开盘 07-08 09:30:00 美东时间
3.82
+0.140
+3.80%
华盛通- 最 高3.855
- 今 开3.70
- 成交量 192.88万股
- 最 低 3.69
- 昨 收 3.68
- 总市值 5.38亿
- 52周最高 4.43
- 市盈率 静 1.01
- 换手率 1.37%
- 52周最低 2.385
- 委 比 -31.63%
- 总股本 1.41亿
- 历史最高 61.625
- 量 比 0.97
- 振 幅 4.48%
- 历史最低 1.79
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Barclays Downgrades Community Health System to Underweight, Maintains Price Target to $3
Barclays analyst Andrew Mok downgrades Community Health System (NYSE:CYH) from Equal-Weight to Underweight and maintains the price target from $3 to $3.
26分钟前
扎克斯行业展望：Tenet Healthcare、Universal Health Services、Acadia Healthcare 及 Community Health Systems
美股医疗类股迎来复苏，行业头部企业通过精简运营、强化成本管控、聚焦高增长服务赛道等举措保障利润空间。 当前医疗行业正处于结构性转型阶段，住院服务需求持续下降，医...
06-29 23:07
Community Health finalizes major Arkansas hospital asset sale
Community Health ( ($CYH) ) has issued an update. On June 1, 2026, Community He...
06-02 06:43
Community Health announces successful $600 million debt tender
Community Health ( ($CYH) ) just unveiled an announcement. On May 6, 2026, Comm...
05-07 05:23
美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
Community Health Systems shares are trading lower after the company reported mixed Q1 financial results.
Community Health Systems shares are trading lower after the company reported mi...
04-22 04:20
Community Health Sys Q1 Adj. EPS $(0.43) Misses $(0.10) Estimate, Sales $2.965B Beat $2.960B Estimate
Community Health Sys (NYSE:CYH) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.10) by 330 percent. This is a 1333.33 percent decrease over losses of $(0.03) per share
04-22 04:17
Earnings Scheduled For April 21, 2026
Companies Reporting Before The Bell • Valmont Industries (NYSE:VMI) is estimate...
04-21 19:11
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
